Faktör V Leiden Mutasyonu Bulunan Genç Myokard Enfarktüsünde Trombüsün Tirofiban İle Trombolizisi

Yıl 2008, Cilt: 5 Sayı: 3, 37 - 39, 01.12.2008

İslamaglu Y Sezen Y Aksakal E Gur M

Öz

19 yaşında erkek hasta şiddetli göğüs ağrısı ile başvurdu. Hastanın EKG’sinde akut anterolateral myokard enfarktüsü bulundu. Hasta primer perkutan girişim için kateterizasyon laboratuvarına alındı. Koroner anjiyografisinde LAD’nin proksimal segmentinde massif trombüs nedeniyle lümen içerisinde dolum defekti tespit edildi. Trombüsün uzunluğu ve koroner yapının uygun olmamasından dolayı perkutan koroner girişim uygulanmadı. Hastada heterozigot faktör V mutasyon vardı. Glikoprotein Iıb/IIIa inhibitörü tirofiban infüzyonu 48 saat uygulandı. 48 saat sonra kontrol koroner anjiyografi yapıldı, intrakoroner trombüsün tamamen kaybolduğu görüldü. Biz Faktör V Leiden mutasyonu bulunan genç myokard enfarktüsünde trombüsün tirofiban ile başarılı bir şekilde eridiğini gösterdik

Anahtar Kelimeler

Faktör V Leiden, Myokard İnfarktüsü, Tirofiban

Effective Thrombolysis with Tirofiban in young Myocardial Infarction case with FV Leiden Mutation

Öz

A 19 year-old man presented with severe chest discomfort. The patient had electrocardiographic evidence of acute anterior-lateral wall myocardial infarction. The patient was taken to the catheterization laboratory for primary percutaneous coronary intervention. Coronary angiography revealed intraluminal filling defects due to a massive thrombus in the proximal segment of the left anterior descending coronary artery. Due to the inappropriate coronary structure and length of the thrombus, percutaneous coronary intervention was not performed. Heterozygous factor V Leiden mutation of patient was positive. Glycoprotein IIb/IIIa inhibitor tirofiban infusion was administered for 48 hours. Control coronary angiography performed at 48 hours showed complete disappearance of the intracoronary thrombus. We present a case of effective thrombolysis with tirofiban in young myocardial infarction case with factor V Leiden mutation

Anahtar Kelimeler

Factor V Leiden, Myocardial infarction, Tirofiban

Kaynakça

• Svensson PJ, Dahback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330:517–22.
• Marz W, Seydewitz, B, Winkelmann N, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345:526–7.
• Gurlertop HY, Gundogdu F, Pirim I, Islamoglu Y, Egerci N, Sevimli S et al. Association between factor V Leiden mutation and coronary artery disease in the northeast region of Turkey. Blood Coagulation and Fibrinolysis 2007; 18:719–722
• Akdemir R, Uyan C. Dissolution of a huge spontaneous coronary artery thrombus with a new antiplatelet agent and coronary angioplasty. International Journal of Cardiology. 2003;89:87–9
• Jayasundera TG, Feldman DN, Marmur JD. Tirofiban-induced Invasive Cardiol 1999; 11:138–40. thrombolysis. J
• Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996; 82:1–32.
• Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT et al. Factor V Leiden (Resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997; 89:2817–2821.
• Lindblad B, Svensson PJ, Dahlba¨ ck B. Arterial and venous thromboembolism with fatal out come and resistance to activated protein C. Lancet 1994;343:917.
• Biasiutti DF, Merlo C, Furlan M, Sulzer I, Binder BR, La¨mmle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 1995;6:456–9.
• Holm J, Zoller B, Svensson PJ, Berntorp E, Erhard TL, Dahlba¨ck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344:952-3.
• Heinrich J, Budde B, Assmann G. Mutation in the factor V gene and the risk of myocardial infarction. N Eng J Med 1995; 333:881.
• Hasdai D, Garrat KN, Holmes DR, Berger PB, Schwartz RS, Bell MR. Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. J Am Coll Cardiol 1996; 28:361–7. Correspondence to: Yahya Islamaoglu, MD, P.K: 112, Department of Cardiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey Tel.: + 90 532 7900683 Fax: + 90 414 3129785 Email: [e-mail]